19 completed. 19 Phase 2, 4 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 19 |
| Phase 3 | 4 | Completed 4 |
| Phase 1 | 3 | Completed 3 |
Follow Encephalomyelitis: new trials by email Literature Review of Encephalomyelitis trials Research Report on Encephalomyelitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low-dose Naltrexone for Post-COVID Fatigue Syndrome Low-Dose Naltrexone, Placebo - Post-Viral Fatigue Syndrome | Phase 2 | Completed | Luis Nacul | 160 | 2024-01-15 | 2026-03-20 |
| Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection Ruconest - Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder) | Phase 2 | Completed | IMMUNOe Research Centers | 40 | 2021-01-11 | 2025-08-11 |
| The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Pyridostigmine Bromide, Placebo - Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Chronic Fatigue Syndrome | Phase 2 | Completed | Brigham and Women's Hospital | 45 | 2020-01-14 | 2022-11-08 |
| Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments 5% lidocaine/5 mg/ml 0.02% estradiol compound cream, Nortriptyline, Placebo cream - Vestibulodynia, Temporomandibular Disorder | Phase 2 | Completed | Duke University | 209 | 2019-11-04 | 2026-03-19 |
| The Comeback Study Preprocessed thawed donor FMT, Preprocessed thawed autologous FMT - Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | Phase 2 | Completed | University Hospital of North Norway | 80 | 2019-02-15 | 2024-02-23 |
| Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome CT38 - Myalgic Encephalomyelitis, Chronic Fatigue Syndrome | Phase 1 / Phase 2 | Completed | LUCINDA BATEMAN, MD | 17 | 2018-07-23 | 2020-05-12 |
| Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS) Cyclophosphamide - Chronic Fatigue Syndrome (CFS), Myalgic Encephalomyelitis (ME) | Phase 2 | Completed | Haukeland University Hospital | 40 | 2015-03-01 | 2021-05-11 |
| Cytokine Inhibition in Chronic Fatigue Syndrome Patients Anakinra, Placebo - Chronic Fatigue Syndrome | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 50 | 2014-06-01 | 2016-05-25 |
| Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS. ReConnect (NADH plus CoQ10), placebo - Chronic Fatigue Syndrome | Phase 2 / Phase 3 | Completed | Hospital Universitari Vall d'Hebron Research Institute | 80 | 2013-01-01 | 2015-02-19 |
| Pacing Activity Self-management for Patients With Chronic Fatigue Syndrome Pacing, relaxation therapy - Chronic Fatigue Syndrome | Phase 2 | Completed | Vrije Universiteit Brussel | 33 | 2011-08-01 | 2015-12-17 |
| B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome Rituximab - Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | Phase 2 | Completed | Haukeland University Hospital | 29 | 2010-10-01 | 2014-09-01 |
| The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial Clonidine, Lactose capsula - Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | Phase 2 | Completed | Oslo University Hospital | 120 | 2010-02-01 | 2012-11-20 |
| Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine Inactivated, Dried, TSI-GSD 104, EEE - Eastern Equine Encephalitis | Phase 2 | Completed | U.S. Army Medical Research and Development Command | 138 | 2008-06-03 | 2019-09-24 |
| Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104 - Eastern Equine Encephalitis | Phase 2 | Completed | U.S. Army Medical Research and Development Command | 138 | 2008-06-03 | 2020-03-17 |
| Drug Intervention in Chronic Fatigue Syndrome Rituximab, Saline (NaCl 0,9 %) (placebo) - Chronic Fatigue Syndrome | Phase 2 / Phase 3 | Completed | Haukeland University Hospital | 30 | 2008-06-01 | 2021-05-11 |
| Transcranial Magnetic Stimulation for Treating Women With Chronic Widespread Pain rTMS, Sham rTMS - Fibromyalgia, Chronic Pain | Phase 2 | Completed | University of Washington | 19 | 2008-02-01 | 2013-05-23 |
| Behavioral Insomnia Therapy With Chronic Fatigue Syndrome Cognitive Behavioral Therapy, Usual Care for Chronic Fatigue Syndrome (Active Control Group) - Chronic Fatigue Syndrome, Behavioral Therapy Targeted to Sleep Problems | Phase 1 / Phase 2 | Completed | Duke University | 24 | 2007-09-01 | 2013-03-01 |
| Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV) valganciclovir - Chronic Fatigue Syndrome | Phase 1 / Phase 2 | Completed | Stanford University | 30 | 2007-05-01 | 2022-05-27 |
| Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome Duloxetine, Placebo - Fatigue Syndrome, Chronic | Phase 2 / Phase 3 | Completed | University of Cincinnati | 60 | 2006-09-01 | 2015-08-21 |
Fatigue Syndrome, Chronic (17) · Fatigue (6) · Fibromyalgia (4) · COVID-19 (2) · Chronic Pain (2) · Encephalomyelitis, Eastern Equine (2) · Pain (2) · Autonomic Nervous System Diseases (1) · Back Pain (1) · Cystitis, Interstitial (1) · Depression (1) · Depressive Disorder, Major (1) · Endometriosis (1) · Epstein-Barr Virus Infections (1) · Herpes Simplex (1)
Nervous System Diseases (19) · Neuroinflammatory Diseases (19) · Chronic Disease (17) · Disease Attributes (17) · Muscular Diseases (17) · Musculoskeletal Diseases (17) · Neuromuscular Diseases (17) · Pathologic Processes (17) · Pathological Conditions, Signs and Symptoms (17) · Signs and Symptoms (7) · Infections (5) · Virus Diseases (5) · RNA Virus Infections (4) · Rheumatic Diseases (4)
Desiccation (2) · Rituximab (2) · Ascorbic Acid (1) · Clonidine (1) · Cognitive Behavioral Therapy (1) · Cyclophosphamide (1) · Duloxetine Hydrochloride (1) · Interleukin 1 Receptor Antagonist Protein (1) · NAD (1) · Naltrexone (1) · Nortriptyline (1) · Phosphoserine (1) · Pyridostigmine Bromide (1) · Relaxation Therapy (1) · Serine (1)
Haukeland University Hospital (3) · Duke University (2) · U.S. Army Medical Research and Development Command (2) · Brigham and Women's Hospital (1) · Hospital Universitari Vall d'Hebron Research Institute (1) · IMMUNOe Research Centers (1) · LUCINDA BATEMAN, MD (1) · Luis Nacul (1) · Oslo University Hospital (1) · Radboud University Medical Center (1) · Stanford University (1) · University Hospital of North Norway (1) · University of Cincinnati (1) · University of Washington (1) · Vrije Universiteit Brussel (1)
United States (10) · Norway (5) · Belgium (1) · Canada (1) · Netherlands (1) · Spain (1)
Robert Rivard, MD (2) · Andrea Nackley, PhD (1) · Andrew Krystal, M.D. (1) · Daphne Kos, PhD (1) · David H. Avery, MD (1) · David Systrom, MD (1) · Jos van der Meer, Prof, PhD, MD (1) · Jose Alegre-Martin, MD, PhD (1) · Jose G Montoya, MD (1) · Lesley M Arnold, MD (1) · Lucinda Bateman, MD (1) · Luis Nacul, MD, PhD (1) · Mark Mayo (1) · Mella Olav, MD, PhD (1) · Olav Mella, MD, PhD (1)
PMID 22039471, PMID 22871021, PMID 23959519, PMID 24493300, PMID 25287104, PMID 25386668, PMID 25660434, PMID 26132314, PMID 26212172, PMID 26357864, PMID 26438161, PMID 27149955, PMID 28265678, PMID 28494812, PMID 29202780, PMID 29284500, PMID 32411717, PMID 33516248, PMID 33899755, PMID 34539356, PMID 35526605, PMID 36269028, PMID 38740499, PMID 38858151, PMID 39697147, PMID 41281561, PMID 42857927
2014 (1), R01HD096331 (1), R21AR053963 (1), R21NR010539 (1)